June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery disease (PAD) revascularization with paclitaxel drug-coated devices. This ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
-
-
March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with ...
-
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD ...
-
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment ...
November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices ...
November 10, 2021
October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...
October 20, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...
June 07, 2021
May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...
May 20, 2021
Feature | Balloon Catheter | By Dave Fornell, Editor
The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...
March 16, 2021
March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials ...
March 12, 2021
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...
November 03, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...
October 18, 2020
October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...
October 18, 2020
Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a ...
September 09, 2020
Feature | Drug-Eluting Balloons | Dave Fornell, Editor
Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high ...
August 06, 2020
July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014 drug-eluting ...
July 07, 2020Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery ...
June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon ...
June 19, 2020
June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal ...
June 18, 2020© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now